EUVIMEDEUVIMED entdecken
FallberichtOpen Access

First-Line [ 177 Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer

Vinay K Giri, Gerald M Kolodny, Marc B Garnick

Journal of Nuclear Medicine · 2025-11 · 66 (11) · 1684-1687

DOI: 10.2967/jnumed.125.270704 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 25.09.2025. Verfasst von Vinay K Giri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Lutetium, Prostatic Neoplasms, Prostate-Specific Antigen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment of metastatic prostate cancer relies on the use of androgen deprivation therapy, which is associated with many side effects, including adverse cardiovascular outcomes. 177Lu-vipivotide tetraxetan ([177Lu]Lu-PSMA-617) is used in the treatment of prostate-specific membrane antigen-expressing metastatic castration-resistant prostate adenocarcinoma. We present the case of a patient with prostate cancer with numerous metastatic lesions who declined androgen deprivation therapy, chemotherapy, and local therapy to the prostate gland and instead received first-line systemic [177Lu]Lu-PSMA-617. He exhibited a significant response in both the primary cancer and its metastatic foci after 2 doses of the treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LutetiumProstatic NeoplasmsProstate-Specific AntigenHumansMaleNeoplasm MetastasisRadiopharmaceuticals

Stichwörter der Autor:innen

first-line [177Lu]Lu-PSMA-617metastaticprostate cancerradiopharmaceutical

Substanzen

LutetiumPluvictoProstate-Specific AntigenRadiopharmaceuticals

Autor:innen und Institutionen

  • Harvard Medical School, Boston, Massachusetts.
  • Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Department of Radiology, Division of Nuclear Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Harvard Medical School, Boston, Massachusetts; mgarnick@bidmc.harvard.edu.

Zitieren

APA

Giri, V. K., Kolodny, G. M., & Garnick, M. B. (2025). First-Line [ 177 Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer. Journal of Nuclear Medicine, 66(11), 1684-1687. https://doi.org/10.2967/jnumed.125.270704

Vancouver

Giri VK, Kolodny GM, Garnick MB. First-Line [ 177 Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer. Journal of Nuclear Medicine. 2025;66(11):1684-1687. doi:10.2967/jnumed.125.270704

BibTeX
@article{Giri2025,
  author = {Giri, Vinay K and Kolodny, Gerald M and Garnick, Marc B},
  title = {First-Line [ 177 Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  volume = {66},
  number = {11},
  pages = {1684--1687},
  doi = {10.2967/jnumed.125.270704}
}
Kostenlos starten →